Coding is partially to blame for rising healthcare costs

Manipulation of codes by both insurers and providers to shift reimbursements in their favor is one reason why the American healthcare system struggles to control costs, according to a new book excerpted in New York Times Magazine.

The book—written by former Times reporter and the current editor-in-chief of Kasier Health News, Elisabeth Rosenthal, MD—doesn’t put all of the blame for runaway healthcare spending on “indecipherable” medical billing. But it does argue that while hospitals, health systems and insurers find ways to financially benefit through coding, patients, especially those without high-quality insurance, are caught in the middle.

Individual doctors don’t like this system, but Rosenthal wrote their own professional associations are part of the problem.

“The American Medical Association owns the copyright to CPT, the code used by doctors. It publishes coding books and dictionaries. It also creates new codes when doctors want to charge for a new procedure. It levies a licensing fee on billing companies for using CPT codes on bills. Royalties for CPT codes, along with revenues from other products, are the association’s biggest single source of income,” she wrote.

Read the full excerpt here: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.